E-LIB Suche - Ergebnisse für: Wander, Seth A

1

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhib..:

Glaviano, Antonino ; Wander, Seth A. ; Baird, Richard D....
Drug Resistance Updates. 76 (2024) - p. 101103 , 2024

Link: https://doi.org/10.1016/..

2

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Seq..:

Bardia, Aditya ; Sun, Sheng ; Thimmiah, Nayana...
Clinical Cancer Research. 30 (2024) 14 - p. 2917-2924 , 2024

Link: https://doi.org/10.1158/..

3

VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER ..:

Hamilton, Erika P ; Ma, Cynthia ; Laurentiis, Michelino De...
Future Oncology. , 2024

Link: https://doi.org/10.1080/..

4

Adverse kidney outcomes of CDK 4/6 inhibitors for metastati..:

Hanna, Paul E. ; Strohbehn, Ian A. ; Moreno, Daiana...
npj Breast Cancer. 9 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

5

Interplay between ESR1/PIK3CA codon variants, oncogenic pat..:

Gerratana, Lorenzo ; Davis, Andrew A. ; Velimirovic, Marko...
Breast Cancer Research. 25 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

6

Venous and arterial thrombosis associated with abemaciclib ..:

Watson, Nathan W. ; Wander, Seth A. ; Shatzel, Joseph J..
Cancer. 128 (2022) 17 - p. 3224-3232 , 2022

Link: https://doi.org/10.1002/..

7

Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Re..:

Brett, Jamie O. ; Herman, Paige E. ; Mayer, Erica L...
Current Breast Cancer Reports. 14 (2022) 4 - p. 222-232 , 2022

Link: https://doi.org/10.1007/..

8

Clinical Implications and Treatment Strategies for ESR1 Fus..:

Brett, Jamie O ; Ritterhouse, Lauren L ; Newman, Erik T...
The Oncologist. 28 (2022) 2 - p. 172-179 , 2022

Link: https://doi.org/10.1093/..

9

Next-generation selective estrogen receptor degraders and o..:

Lloyd, Maxwell R. ; Wander, Seth A. ; Hamilton, Erika..
Therapeutic Advances in Medical Oncology. 14 (2022) - p. 175883592211136 , 2022

Link: https://doi.org/10.1177/..

10

Immunogenicity of SARS-CoV-2 vaccines in patients with brea..:

Denault, Elyssa ; Nakajima, Erika ; Naranbhai, Vivek...
Therapeutic Advances in Medical Oncology. 14 (2022) - p. 175883592211193 , 2022

Link: https://doi.org/10.1177/..

11

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinica..:

Wander, Seth A ; O'Brien, Neil ; Litchfield, Lacey M...
The Oncologist. 27 (2022) 10 - p. 811-821 , 2022

Link: https://doi.org/10.1093/..

12

Pilot study to assess prolonged overnight fasting in breast..:

O'Donnell, Elizabeth ; Shapiro, Yael ; Comander, Amy...
Breast Cancer Research and Treatment. 193 (2022) 3 - p. 579-587 , 2022

Link: https://doi.org/10.1007/..

13

ESR1 mutation as an emerging clinical biomarker in metastat..:

Brett, Jamie O. ; Spring, Laura M. ; Bardia, Aditya.
Breast Cancer Research. 23 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

14

HGAL inhibits lymphoma dissemination by interacting with mu..:

Jiang, Xiaoyu ; Lu, XiaoQing ; Gentles, Andrew J....
Blood Advances. 5 (2021) 23 - p. 5072-5085 , 2021

Link: https://doi.org/10.1182/..

15

Cyclin-dependent kinase 4 and 6 inhibitors for hormone rece..:

Spring, Laura M ; Wander, Seth A ; Andre, Fabrice...
The Lancet. 395 (2020) 10226 - p. 817-827 , 2020

Link: https://doi.org/10.1016/..